N/A
Completed N=15
Identifying the Anti-Blood-Clotting Compounds in Garlic
Arteriosclerosis · Intracranial Arteriosclerosis
Source: ClinicalTrials.gov NCT00200785 ↗
Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jan 2010
Primary outcomePrimary: Percent Platelet Aggregation — 71.4; 72.5 percent platelet aggregation
Summary
This study will seek to identify the compound(s) in garlic that is (are) responsible for its ability to prevent the formation of blood clots (prevent platelet aggregation) and to determine the maximally effective dose and duration of the benefits. This study will also determine whether "cooked" garlic (garlic powder added to boiling water, no allicin present) is as effective as "fresh" garlic (garlic powder added to ambient water, high allicin present) and, if more than one compound is involved, and whether their combined effects are more significant than the effects of each compound alone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Platelet Aggregation |
71.4; 72.5 | — |
| SECONDARY Electrical Impedance in Ohms |
13.8; 15.0 | — |
Eligibility Criteria
Inclusion Criteria
- Body mass index of 19 to 30 kg/m2
- Plans to remain in the study area for the next year
- Willingness to abstain from nonsteroidal anti-inflammatory drugs (NSAID drugs for 1 week prior to each study test
- Willingness to abstain from consuming garlic and significant amounts of onion, chocolate, or purple grape juice for 3 days prior to each study test
- Willingness to participate in all study tests
Exclusion Criteria
- Pregnancy or breast-feeding
- Serious medical condition
- Allergy to garlic or wheat
- Tobacco use
- Excessive alcohol consumption
- Under psychiatric care
Data sourced from ClinicalTrials.gov (NCT00200785). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.